On January 3rd 2018 the World Health Organization declared the prequalification of a new typhoid conjugate vaccine specifically targeting low- and middle income countries. The news came to us as a pleasant surprise and we are all grateful to Bharat Biotech International who against all odds took the initiative to manufacture and invest in this neglected disease called typhoid.

In the November 2017 issue of the National Geographic Magazine, Cynthia Gorney and William Dianiels painted a vivid picture of why and how vaccines play pivotal roles in our societies. The article revolves around pneumonia, pneumococcus (bacteria that cause pneumonia), and pneumococcal conjugate vaccine.

The study is enrolling otitis media cases to elucidate the effectiveness and impact of PCV-10 using the before (pre-vaccine) after (post-vaccine) design. This outpatient based project will give additional attention on the impact of PCV-10 on cross protecting serotypes and Non-Typable H.influenzae (NTHi).

This study aims to measure the Impact of PCV will be measured in different age groups to understand the direct and indirect effects.

To Estimate prevalence of pneumococcal carriage and serotype distribution among newborn and children